Search the Newsreel

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. announced its second quarter 2026 financial results, highlighting key advancements in its clinical pipeline. The company expects to report top-line data for its EVO756 atopic dermatitis (AD) Phase 2b trial in September 2026 and has initiated a Phase 2b trial for EVO756 …

Evommune, Inc. 2Q 2026: Revenue $0 Net loss $53.9M — 10-Q Summary

Evommune, Inc. reported no revenue and a net loss of $53.9 million for the second quarter of 2026, an increase from a $28.1 million net loss in the prior year. The company ceased development of EVO756 for chronic spontaneous urticaria but continues trials for …

Evommune Inc (EVMN) Stock News Today

This article provides current stock information for Evommune Inc (EVMN), including its market performance, market cap, and a note that more news will be coming soon. As of August 7th, the stock closed at 14.080 USD, up 5.49%. The platform offers news, analysis, financials, …

Evommune Inc (EVMN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Evommune (EVMN) Earnings Date and Reports 2026

896,700 Shares in Evommune, Inc. $EVMN Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC recently acquired 896,700 shares of Evommune, Inc. (NYSE:EVMN) valued at approximately $20.6 million, giving them a 2.49% stake in the biotech company. Despite a "Moderate Buy" consensus rating and an average price target of $45.62, Evommune shares opened at $11.65, …

Evommune stock: H.C. Wainwright reiterates Neutral rating

H.C. Wainwright has reiterated a Neutral rating on Evommune Inc (EVMN) following a clinical trial update. The company recently dosed the first patient in its Phase 2b trial for EVO756, an oral small molecule for migraine treatment, with top-line data expected next year. Despite …

Defilade Capital Management L.P. Boosts Position in Evommune, Inc. $EVMN

Defilade Capital Management L.P. significantly increased its stake in Evommune, Inc. (NYSE:EVMN) by 215% in the first quarter, now owning 678,589 shares valued at $15.6 million. Despite this boost, Evommune's shares opened at $11.23, near its 52-week low, and analyst sentiment is mixed with …

Perceptive Advisors LLC Buys Shares of 448,350 Evommune, Inc. $EVMN

Perceptive Advisors LLC has acquired 448,350 shares of Evommune, Inc. (NYSE:EVMN) in the first quarter, a position valued at approximately $10.3 million, representing 1.24% ownership. Despite a consensus "Moderate Buy" rating from analysts with a target price of $45.62, the stock currently trades near …

Evommune doses first patient in migraine prevention trial

Evommune, Inc. has initiated a Phase 2b clinical trial for EVO756, an oral small molecule antagonist, for the prevention of migraines. The trial will enroll approximately 330 adults with refractory migraine, aiming to evaluate the efficacy of EVO756 in reducing monthly migraine days. Top-line …

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

Evommune has started a Phase 2b clinical trial for its MRGPRX2 inhibitor, EVO756, for the preventive treatment of migraine. EVO756 is an oral small molecule designed to inhibit three key neuropeptides that trigger migraine signals by targeting MRGPRX2 receptors in human trigeminal neurons and …

Evommune Inc (EVMN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Evommune Inc (EVMN), including its current stock price, market capitalization, and a general overview of its financials and discussions. It also offers information regarding dividend and stock split history, although no specific data is present in the provided text. …

Evommune Inc (EVMN) Cash Flow

This article provides details on the cash flow statement for Evommune Inc (EVMN), including operating, investing, and financing cash flows from Q1 FY2026. It highlights specific financial figures such as operating cash flow of -27.50M, investing cash flow of -85.36M, and financing cash flow …

Evommune Inc (EVMN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Evommune Inc (EVMN), including its major shareholders and institutional holdings as of recent updates. It breaks down the proportion of shares held by different entities like EQT Partners AB, EQT Life Sciences, and RA Capital Management, LP, …

EVMN|Evommune Inc|Price:11.360|Chg%:+0.060

This article provides a company profile for Evommune Inc (EVMN), detailing its current stock performance, market capitalization, and key executive leadership. It lists significant personnel including Dr. Eugene A. Bauer, Ms. Janice Drew, Mr. Luis Pena, and others, highlighting their roles and in some …

TradingKey

This article provides the quarterly and annual balance sheets for Evommune Inc (EVMN), detailing the company's financial health including assets, liabilities, and shareholders' equity. It presents data for FY2026Q1, FY2025Q4, and FY2025Q2, and includes frequently asked questions about balance sheet metrics, definitions of financial …

Evommune (EVMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline - Analyst Consensus Shift

Long term debt to total assets ratio of Evommune, Inc. – BX:EVMNUSD

This article focuses on the long-term debt to total assets ratio of Evommune, Inc. (BX:EVMNUSD), providing financial data for the company. The content appears to be a financial data page from TradingView, without additional analytical text or detailed news. It simply presents the ratio's …

Price to earnings forward of Evommune, Inc. – NYSE:EVMN

EVMN Forecast — Price Target — Prediction for 2027

Evommune Inc. (EVMN) Q1 2026 Earnings: EPS Surprise Beats Estimates by 15.6% as Stock Gains $4.87